2. Academic Validation
  3. Agarotetrol attenuates spinal cord injury by targeting PPARγ to modulate microglial activation

Agarotetrol attenuates spinal cord injury by targeting PPARγ to modulate microglial activation

  • Exp Cell Res. 2026 May 1;458(1):114947. doi: 10.1016/j.yexcr.2026.114947.
Shaofeng Fu 1,  Chao Yan 1,  Bohui Liu 1,  Guangxuan Yan 2,  Yongchao Li 2,  Kai Tang 2,  Heng Wang 2,  Ruiqing Cui 3,  Yongxiong He 4
Affiliations

Affiliations

  • 1 Department of Integrated Traditional Chinese and Western Medicine, The Fourth Hospital of Inner Mongolia, Hohhot, China.
  • 2 Department of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, China.
  • 3 Department of Integrated Traditional Chinese and Western Medicine, The Fourth Hospital of Inner Mongolia, Hohhot, China. Electronic address: [email protected].
  • 4 Department of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, China. Electronic address: [email protected].
PMID: 41720447 DOI: 10.1016/j.yexcr.2026.114947
Abstract

Secondary spinal cord injury (SCI) is characterized by sustained neuroinflammation and microglial activation. Agarotetrol (AH1), a principal bioactive component of agarwood, has demonstrated neuroprotective potential, yet its precise mechanism in SCI remains incompletely understood. A rat SCI model was established using vascular clip compression. AH1 was administered orally for 28 days. Behavioral tests, histology, immunofluorescence, Western blot, and ELISA were used to evaluate functional recovery, neuroinflammation, and microglial activation. In vitro, BV-2 cells were treated with AH1 and LPS to assess inflammatory responses and PPARγ involvement. AH1 treatment significantly improved motor function, reduced neuronal loss, and suppressed pro-inflammatory cytokine levels in SCI rats. In vitro, AH1 inhibited LPS-induced microglial activation and cytokine release. Mechanistically, AH1 directly bound to the PPARγ ligand-binding domain, enhanced PPARγ/PGC-1α/SRC-1 interaction, and promoted anti-inflammatory transcription. PPARγ knockdown abolished AH1's effects both in vivo and in vitro. AH1 attenuates neuroinflammation and promotes functional recovery after SCI by targeting PPARγ to modulate microglial polarization. These findings highlight AH1 as a potential therapeutic agent for SCI.

Keywords

Agarotetrol; Microglial activation; Neuroinflammation; PPARγ; Spinal cord injury.

Figures
Products
Inhibitors & Agonists